Samsrita Labs Ltd
₹ 18.9
5.00%
25 Apr
- close price
About
Incorporated in 1996, Samsarita Labs Ltd is
in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
Key Points
- Market Cap ₹ 28.0 Cr.
- Current Price ₹ 18.9
- High / Low ₹ 32.4 / 12.2
- Stock P/E
- Book Value ₹ 8.16
- Dividend Yield 0.00 %
- ROCE -1.79 %
- ROE -2.13 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -3.60%
- Company has a low return on equity of -3.24% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00 | 3.97 | 3.69 | 1.28 | 0.62 | 1.90 | 1.43 | 0.01 | 0.02 | 0.02 | -0.00 | -0.00 | |
| 0.01 | 4.03 | 3.73 | 1.61 | 1.64 | 4.13 | 3.46 | 0.92 | 0.43 | 1.01 | 0.25 | 0.26 | |
| Operating Profit | -0.01 | -0.06 | -0.04 | -0.33 | -1.02 | -2.23 | -2.03 | -0.91 | -0.41 | -0.99 | -0.25 | -0.26 |
| OPM % | -1.51% | -1.08% | -25.78% | -164.52% | -117.37% | -141.96% | -9,100.00% | -2,050.00% | -4,950.00% | |||
| 0.08 | 0.09 | 0.05 | 0.01 | -0.00 | 0.11 | 0.16 | 0.15 | 1.91 | 0.29 | -0.00 | -0.00 | |
| Interest | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.01 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Depreciation | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.01 | 0.01 | 0.01 | 0.01 | -0.00 | -0.00 | -0.00 |
| Profit before tax | 0.07 | 0.03 | 0.01 | -0.32 | -1.02 | -2.14 | -1.89 | -0.77 | 1.49 | -0.70 | -0.25 | -0.26 |
| Tax % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| 0.07 | 0.03 | 0.01 | -0.32 | -1.02 | -2.14 | -1.89 | -0.77 | 1.50 | -0.71 | -0.25 | -0.26 | |
| EPS in Rs | 0.13 | 0.06 | 0.02 | -0.31 | -0.87 | -1.55 | -1.28 | -0.52 | 1.01 | -0.48 | -0.17 | -0.18 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | % |
| TTM: | -4% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -19% |
| 3 Years: | -11% |
| 1 Year: | 9% |
| Return on Equity | |
|---|---|
| 10 Years: | -5% |
| 5 Years: | -1% |
| 3 Years: | -3% |
| Last Year: | -2% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.39 | 5.39 | 5.39 | 10.26 | 11.76 | 13.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | -1.62 | -1.60 | -1.58 | -1.90 | 0.11 | -1.01 | -2.38 | -3.01 | -1.51 | -2.22 | -2.47 | -2.73 |
| -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 1.32 | 1.79 | 2.34 | 2.74 | 2.08 | 2.20 | 2.43 | |
| 0.48 | 2.54 | 1.74 | 0.13 | 0.36 | 1.11 | 2.71 | 3.09 | 1.16 | 0.96 | 1.10 | 1.17 | |
| Total Liabilities | 4.25 | 6.33 | 5.55 | 8.49 | 12.23 | 15.23 | 16.93 | 17.23 | 17.20 | 15.63 | 15.64 | 15.68 |
| -0.00 | -0.00 | -0.00 | -0.00 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 3.26 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | 0.92 | 2.15 | 3.03 | 3.26 | 3.26 | 3.26 | 3.26 | -0.00 |
| Investments | 0.85 | -0.00 | -0.00 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 |
| 3.40 | 6.33 | 5.55 | 3.62 | 6.42 | 8.17 | 9.00 | 9.08 | 9.06 | 7.49 | 7.50 | 7.55 | |
| Total Assets | 4.25 | 6.33 | 5.55 | 8.49 | 12.23 | 15.23 | 16.93 | 17.23 | 17.20 | 15.63 | 15.64 | 15.68 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.00 | -0.76 | -0.02 | -0.06 | -3.28 | -3.46 | -1.07 | -0.34 | -0.40 | 0.66 | -0.13 | ||
| -0.85 | 0.85 | -0.00 | -4.87 | -0.94 | -1.26 | -0.89 | -0.23 | -0.00 | -0.00 | -0.00 | ||
| 0.85 | -0.00 | -0.00 | 4.87 | 4.53 | 4.40 | 1.97 | 0.55 | 0.40 | -0.67 | 0.13 | ||
| Net Cash Flow | -0.00 | 0.09 | -0.02 | -0.06 | 0.31 | -0.32 | 0.01 | -0.02 | 0.01 | -0.00 | -0.00 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 528.65 | 498.54 | 932.46 | 1,689.60 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | |||
| Inventory Days | -0.00 | -0.00 | -0.00 | 608.33 | -0.00 | -0.00 | ||||||
| Days Payable | 365.00 | |||||||||||
| Cash Conversion Cycle | 528.65 | 498.54 | 932.46 | 1,932.93 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | |||
| Working Capital Days | 296.96 | 328.40 | 903.95 | 2,254.76 | 991.26 | 1,115.42 | 146,000.00 | 108,770.00 | 84,132.50 | |||
| ROCE % | 2.11% | 0.79% | 0.26% | -5.26% | -10.08% | -16.39% | -13.27% | -5.43% | 9.87% | -4.56% | -1.71% | -1.79% |
Documents
Announcements
-
Board Meeting Intimation for Increase In Authorized Capital Of The Company And Raising Of Funds Through Issue Of Equity Shares, Convertible Warrants Or Any Such Other Securities On Preferential Basis
17h - Board meeting on 30-Apr-2025 to approve capital increase, fund raise, stake acquisition, and MOA amendment.
- AUIDTED FINANCIAL RESULTS OF THE COMPANY FOR THE YEAR ENDED 31-03-2025 18h
-
INTIMATION FOR APPOINTMENT OF INTERNAL AUDITOR AND SECRETARIAL AUDITOR OF THE COMPANY
18h - Approved FY25 audited results; appointed internal and secretarial auditors for FY26 and five years respectively.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 26-04-2025 For Approval Of Audited Financials Of The Company For The Quarter And Year Ended On 31-03-2025
19h - Approved FY25 audited results; appointed internal and secretarial auditors for FY26 and five years respectively.
-
Board Meeting Intimation for Approval Of The Audited Financial Results Of The Company Along With Audit Report For The Quarter And Year Ended On 31.03.2025
21 Apr - Board meeting on 26-Apr-2025 to approve audited results for quarter and year ended 31-Mar-2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Products & Services:[1][2]
a) Stem Cell R&D:
Stem Cell Research & Therapy,
Regenerative Medicine, Bio-artificial
organ scaffolds development, nano-biotechnology, Nano-formulation of
cancer Drugs, Molecular genetics,
and Molecular virology, Stem cell
and Cord blood banking
b) New Drug Discovery:
Wilson’s disease, Non-Alcoholic Steatohepatitis (NASH), Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington’s disease
c) RNA Interference:
For developing a new panel of miRNAs
as a novel Bio Marker
d) Medical Devices:
Extra-corporeal liver support devices, Bioengineering implantable humanized nerve conduits, implantable nanochips carrying insulin-producing cells, extra-corporeal devices, etc.
e) Molecular Diagnostics:
DNA, RNA, and chromosomal based tests
and Pre-natal and pre-implantation genetic diagnostics, etc.
f) Contract Research Organization:
Synthetic Chemistry, Medicinal Chemistry, Drug Development, API’s process research, scale-up activity, Natural products research, and Analytical services